FAST NEWS: Henlius expects first-ever annual profit on strong drug sales
The latest: Shanghai Henlius Biotech Inc. (2696.HK) said on Monday it expects to report a net profit of 500 million yuan ($69.5 million) or more for 2023, reversing a loss of 695 million…
FAST NEWS: Henlius swings to the black on strong sales growth
The latest: Shanghai Henlius Biotech Inc. (2696.HK) on Wednesday reported a net profit of 408 million yuan ($56.2 million) in the first three quarters of this year, reversing a loss of…
Debt pressures cast cloud over Fosun Pharma results
The drugmaker eked out a 0.16% rise in first-half revenue, but underlying net profit slipped 26% as waning sales of Covid treatments and foreign exchange losses squeezed earnings Key Takeaways:…
CHINA BULLETIN: Weak Economic Signals All Around
In this week’s issue weak signals in trade and inflation, and LinkedIn links out. On a scale of 1 to 100, we give the week a 40 for offshore-listed China stocks.
Fosun Pharma, CanSino take different paths as Covid lift fade
The pair of companies that got strong shots from different Covid vaccines are telling different stories in their latest quarterly results as the pandemic draws down Key Takeaways: Fosun Pharma’s…
FAST NEWS: Henlius Biotech’s revenue doubles in first quarter
The latest: Shanghai Henlius Biotech Inc. (2696.HK) reported its revenue soared 97.2% to 996 million yuan ($145 million) in the first quarter, according to a business update released on Sunday.…
CHINA BULLETIN: Europe Calls on China
In this week’s issue EU leaders come calling on China, Evergrande restructures and Airbus invests. On a scale of 1 to 10, we give the week a 5 for offshore-listed China stocks.